Program
Keynote Speakers
Pre-Meeting Symposium Speakers
Invited Speakers
Pioneer Lecturer
Lowenthal Lecturer
Provisional Program
Thursday, 23 April 2009
Accreditation Board Meeting
ANSZNMT Committee Meeting
ANZSNM Federal Committee Meeting
Friday, 24 April 2009
Pre-Meeting Symposium at Dockside
ANZAPNM Council Meeting
Golf with Gordon
Tour of ANSTO - Limited places
Saturday, 25 April 2009
Plenary Session
ANZSNMT Symposium, including RadPharm Award
ANZAPNM Symposium, including ANZAPNM Registrar Award
Physicists SIG
Nurses SIG
Radiopharmacists SIG
Welcome Reception
Nuc?s Function
Sunday, 26 April 2009
Plenary Sessions
Lowenthal Lecture
Pioneer Lecture
Concurrent Sessions, including ANSTO and Mallinckrodt Awards
ANZSNM AGM
Gala Dinner
Monday, 27 April 2009
Plenary Sessions
Concurrent Sessions
Edwina Adams
Edwina worked clinically as a nuclear medicine technologist for approximately 20 years. The past 13 years have been as an educator at The University of Sydney. Edwina's research interests are in workforce issues and clinical education. Her PhD investigating the Australian nuclear medicine technologist workforce will be completed this year.
Dr Stephen Allwright
Nuclear Medicine Physician, trained in paediatric nuclear medicine at Childrens Hospital Los Angeles and currently in private practice at the Mater Hospital in Sydney and at Dee Why Nuclear Medicine. Developed an interest in sports medicine and musculoskeletal bone scanning. Co-authored Atlas of Nuclear Imaging in Sports Medicine Dr Bob Cooper and Dr Jock Anderson.
Dr Beata Bajorek
Dr Beata Bajorek is an Academic Pharmacist for the Faculty of Pharmacy, University of Sydney and Northern Sydney Central Coast Health. She has practised as a clinical pharmacist and had the privilege of being the Alexander Schmidt Research Fellow at the Clinical Practice Advancement Centre, University Health System Consortium in Chicago, USA 2001-2. She has served as an expert speaker and reviewer for the National Prescribing Service, Pharmaceutical Society of Australia and Australian College of Pharmacy Practice; education coordinator and office bearer for the Society of Hospital Pharmacists of Australia (NSW); and committee member of the NSW Therapeutic Assessment Group (TAG). Her clinical and research endeavours focus on the Quality Use of Medicines, specifically medication safety. Dr Bajorek writes generously for the health profession in journals as disparate as The Medical Journal of Australia, Journal of the American Geriatrics Society and Australian Journal of Pharmacy. She is a highly experienced clinical educator, lecturing on pharmacology and pharmacotherapeutics, evidence-based medicine and research methods, to medical and allied health professionals (GPs, nurses, optometrists, radiographers, pharmacists) at key education events. In 2007, she received two Faculty awards for Outstanding Teaching and Support for the Student Experience.
Dr Thomas Beyer
Thomas Beyer graduated in Physics at the Leipzig University (Germany) and got his PhD in Medical Physics from Surrey University (UK). During his studies he became involved in the development and clinical testing of the first PET/CT prototype (1992-2000) before joining Siemens/CTI PET Systems as an International PET/CT specialist. In 2002 he became a Research Associate in Nuclear Medicine and Radiology and PET/CT project manager at Essen University Hospital (Germany). In 2006 he became teaching professor for Experimental Nuclear Medicine and joined Timaq medical imaging Inc, a Zurich-based Imaging CRO. In 2007 he moved to Philips Medical Systems as International Manager Clinical Science Nuclear Medicine. Since 2008 Dr Beyer is CEO of cmi-experts, a Swiss-based service provider in multi- modality imaging. He is a member of various national and international Medicine organizations, a co- opted member of the European Association of Nuclear Medicine (EANM) Physics Committee and Head of the New Technology working group at the Association of Imaging Producers and Equipment Suppliers (AIPES).
Dr Robert Cooper
Bob Cooper is a physician in Nuclear Medicine practicing in both the public sector at Royal North Shore Hospital and in private at the Mater Hospital and Dee Why in Sydney. Bob was the first Australian to complete his Nuclear medicine training at the University of Michigan USA, one of the institutions with a strong history of training Australians.
He has a particular interest in bone scanning especially as it relates to Sports Medicine.
Dr Anthony Freeman
Dr Anthony Freeman is a Consultant Cardiologist and VMO to the Prince of Wales Hospital participating on the on call roster to the Coronary Care Unit. He received a Doctorate from UNSW in the field of Nuclear Cardiology and is the cardiologist responsible for Nuclear Cardiology at the Prince of Wales Hospital. He has been involved in the setting up of two busy outpatient CT coronary angiography laboratories and personally reported over 2,000 CT coronary angiograms. He has obtained Level 3 cardiac CT accreditation in the US. He has published and lectured in field of CT and Nuclear Cardiology.
Professor Hosen Kiat
Professor Hosen Kiat graduated from Monash University. He is Professor and Chair, Cardiology, Australian School of Advanced Medicine, Macquarie University; Professor of Medicine, UWS School of Medicine; Medical Director of the Cardiac Health Institute which conducts collaborative research with UWS, CSU and the University of Indonesia; and staff specialist at the Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney.
Professor Tomas Kron
PhD, FACPSEM, FCCPM, FInstP
Pre-Meeting Symposium Speaker
Tomas Kron was born and educated in Germany. After his PhD at the University of Frankfurt he migrated to Australia in 1989 to work in MRI research at the University of NSW. In 1990 he took up a position as clinical medical physicist at the Prince of Wales Hospital in Sydney and became Chief Physicist at the Newcastle Mater Hospital in 1993 after a spending some time at the Illawarra Cancer Care Centre. From 2001 to 2004 Tomas worked at the London Regional Cancer Centre in Canada on the commissioning of one of the first helical tomotherapy units. Since 2005 he is principal research physicist at Peter MacCallum Cancer Centre and Honorary Professor at RMIT and Wollongong Universities.
Tomas has an interest in dosimetry of ionising radiation, treatment verification and image guided radiotherapy. He has co-authored a radiotherapy textbook, edited a book on Radiation Protection in Medicine and published more than 80 papers in refereed journals. Over the years he has maintained also an interest in education reflected in many invited conference presentations, consultancies for the International Atomic Energy Agency (IAEA) and the International Society for Radiation Oncology (ISRO), and involvement in workshops and training in Australasia. Tomas Kron is currently president of the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) the professional organisation representing medical physicists and biomedical engineers in Australia and New Zealand.
Dr John McKay
John McKay has had a long career in Nuclear Medicine having been working in the specialty since the early 70's.
Following initial training at the POW Hospital Randwick where he was the first Registrar in Nuclear Medicine he "temporarily" relocated to Melbourne as Staff Specialist in Nuclear Medicine at the Royal Melbourne Hospital. An appointment as the initial Director in Nuclear Medicine at the Austin Hospital followed. During his time at Austin the Department grew to be one of the most influential within Australia. Under his leadership Australia's first PET centre with a dedicated medical cyclotron and radiochemistry laboratory was established.
Some years ago the lure of the sea became too much and he shifted to the Bayside area where he commenced working at Monash Medical Centre as sole Director and Specialist. In those few years the department has grown to include four major hospitals and now employs seven Nuclear Medicine Specialists under the wing of the Southern Health Care Network. It continues to be source of great pleasure that all of these Consultants have commenced their careers in Nuclear Medicine under his Directorship.
Over the years Dr McKay has held major leadership roles in the Society including President. A longstanding interest in the education of technologists has been evidenced by many years of service as Chairman of the Accreditation Board of the ANZSNM.
Dr Helen Nadel
Dr Helen Nadel is a Pediatric Radiologist and Nuclear Medicine physician currently on staff in the Department of Radiology at British Columbia Children?s Hospital in Vancouver, Canada where she is Head of the Division of Nuclear Medicine. Helen is an Associate Professor of Radiology and has many publications in the field of Paediatric Nuclear Medicine and lectures extensively in her field. While she describes herself as a generalist, she has a particular interest in the area of oncology and is the Vice Chair for Nuclear Medicine of the Radiology Committee of the Children?s Oncology Group. She is past president of the Pediatric Council of the Society of Nuclear Medicine and of the Pacific Northwest Chapter Society of Nuclear Medicine. She is most proud to be the mother of two daughters Frani and Daniella, and the wife of Tevy Goodman.
Dr Sharon Oultram
Sharon is the Senior Radiation Therapy Educator at the Newcastle Calvary Mater Hospital, Department of Radiation Oncology. She trained as a radiation therapist over 25 years ago in Canada. In 2003, Sharon took on the role of Clinical RT Educator. She is currently completing a Masters in Health Science Education.
Associate Professor Thomas Pfluger
Associate Professor Pfluger was born 1960 in Munich, Germany. After his university education in Munich, he got the licensure as physician in 1986. From 1986 to 1993, he worked as a resident for Radiology at the University of Munich. In 2000, he was appointed as Associate Professor. From 2001 until now he is consultant for Nuclear Medicine and Radiology at the University of Munich.
Professor David W Townsend
David W. Townsend PhD is Professor of Medicine and Radiology and Director of the Molecular Imaging and Translational Research Program at the University of Tennessee Medical Center in Knoxville, Tennessee. He co-invented the combined PET/CT scanner, named by TIME Magazine as the Medical Invention of the Year 2000. In 2004, he received the Academy of Molecular Imaging Distinguished Clinical Scientist Award and in 2006 he was elected a Fellow of the IEEE.
R Michael Tuttle, MD
Dr Tuttle, originally from Kentucky, attended medical school at the University of Louisville in Louisville Kentucky. He went on to do his Internship and Residency in Internal Medicine at Dwight David Eisenhower Army Medical Center in Augusta Georgia. This was followed by a two year fellowship in Endocrinology and one year of laboratory based training in molecular biology at Madigan Army Medical Center in Tacoma Washington.
After 3 years as a staff endocrinologist at Madigan Army Medical Center, he transferred to Walter Reed Army Medical Center in Washington DC. At Walter Reed he served as Assistant Chief of the Thyroid clinic, and Assistant Chief of the Department of Clinical Investigations. Upon leaving the Army, Dr Tuttle joined the Endocrine Service at Memorial Sloan Kettering Cancer Center in August of 1999. Dr Tuttle's clinical and research interests continue to center on the management of advanced thyroid cancer.
Dr Ivan Ho Shon
Pre-Meeting Symposium Speaker
Dr Ho Shon is a staff specialist in Nuclear Medicine and PET at Liverpool and Royal North Shore hospitals and is a Conjoint Lecturer of the University of New South Wales and the University of Sydney. His interests include hybrid imaging in therapy planning and has close collaborations with Radiation Oncology.
Dr Shalini Vinod
Pre-Meeting Symposium Speaker
Dr Shalini Vinod is a staff specialist in radiation oncology at Liverpool Hospital and a conjoint senior lecturer at UNSW. Her clinical interests are lung cancer, breast cancer and gynaecological cancers. She participates in an active Lung Cancer Multidisciplinary Team in South Western Sydney in close collaboration with Nuclear Medicine.
Juan Manuel Podadera
Juan Manuel Podadera Veterinarian. I graduated from veterinary school in Argentina in 2000. I have been working in private practice in Argentina and Australia for the past 6 years. Currently I am undergoing specialist training in Imaging for the University of Sydney Veterinary Teaching Hospital. My main areas of interest are Equine Radiology, Equine MRI and Equine nuclear medicine.
Dr Richard Smart
Richard Smart obtained his initial training in Medical Physics at the Sheffield Royal Infirmary, UK, where he completed his PhD through the University of Sheffield. He is currently the Chief Physicist in Nuclear Medicine and Radiation Safety Officer at St George Hospital and holds a conjoint Associate Professor appointment with the University of NSW. He is a member of the NSW Radiation Advisory Council.
Professor Robert Howman-Giles
Pioneer Lecturer
Professor Robert Howman-Giles is Professor of Nuclear Medicine and Head, section of nuclear medicine in the Discipline of Imaging and Discipline of Paediatrics and Child Health, University of Sydney. He is Head of the Department of Nuclear Medicine at the Children?s Hospital at Westmead and has published extensively on the use of nuclear medicine and bone mineral density in paediatrics with over 140 publications in peer reviewed journals, 17 book chapters and 1 book. He has presented many papers and has been an invited speaker at many national and international meetings. His work has resulted in his membership to many committees nationally and internationally. Professor Howman-Giles has a particular interest in the applications of nuclear medicine and PET in paediatric oncology, bone, renal and biliary disorders and the investigation of lymphatic disorders in children and adults.
Ms Jocelyn Towson
Lowenthal Lecturer
Ms Jocelyn Towson has a Masters degree in Radiation Physics and Biology and is accredited in Ionizing Radiation Safety by ARPAB. Jocelyn has been employed as the Radiation Safety Officer at RPAH since 1985, where her work includes practical protection measures, advice on radiation dose and risk, oversight of regulatory requirements, training and quality assurance for radiation safety. Teaching activities include lectures for physics students in MSc courses at the Universities of Sydney and Wollongong, NMT students at the University of Sydney, the Hursog course on CT for Nuclear Medicine Technologists and preparation of material for the IAEA Distance Assisted Training program for nuclear medicine technologists. She is currently contributing on behalf of NSW Health to the implementation of the APANSA Code on Security of Sources and review of the draft ARPANSA Safety Guides on Nuclear Medicine and the Predisposal Management of Radioactive Waste.
Mark Wallenmeyer
Mr. Wallenmeyer, MBA, is a certified nuclear medicine technologist and currently serves as the President of the SNMTS in the United States. He also serves as an Assistant Professor and Clinical Coordinator for a web-based nuclear medicine program. Along with these duties, Mr. Wallenmeyer also serves as CEO of Trajecsys Corporation.
Awards
Poster Prizes
ANSTO Nuclear Medicine Award
ANZAPNM Registrar Award
Mallinckrodt Award for Nuclear Medicine Technologist
Radpharm Award
Please send an email to m.au if you wish your abstract to be considered for one of the Awards.
Poster Prizes
Poster Award Applications
1. Please nominate your poster for the Poster Award by selecting this category when submitting your abstract.
2. An abstract must be provided to qualify for this Award.
3. A JPG of the poster as well as 1 or 2 PowerPoint slides giving a summary of their work is to be submitted to m.au by 31 March 2009 for review and first round of judging.
4. Selected finalist posters will be judged based on marking criteria.
The winners of the poster prizes may have their slides used by the nominated presenter of the "highlights of the conference presentation" at the conclusion of the conference.
Sponsored by 
ANSTO Nuclear Medicine Award
RULES
1.The Award will be made for significant innovation in research or clinical practice in the field of Nuclear Medicine. Applicants are urged to submit the paper for oral or poster presentation at an international medical specialty meeting, with acceptance being a significant pointer to the merit of the work for the award. The objective of the award is to highlight the high calibre of Australian Nuclear Medicine and ANSTO's role in supporting it, to as diverse an audience as possible - particularly the Nuclear Medicine referral base.
2. Entrants for the Award may be from any discipline within the field of Nuclear Medicine. The entrant must be a financial member of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) of at least six months standing.
3. The Award is not open to employees of ANSTO, or for work or research carried out whilst an employee of ANSTO.
4. The material shall be presented as an oral paper at the Annual Meeting of the ANZSNM.
5. Candidates must provide a statement countersigned by his or her department head indicating the extent of assistance received during the course of the work. This statement plus four copies of the full manuscript shall be in the hands of the Scientific Programme Organiser at least four weeks prior to the Conference to enable short-listing and preliminary review of the work. All candidates will be notified of the outcome of this process at least one week before the conference..
6. The recipient of the Award must undertake to submit the written paper to the Editor of the ANZSNM Journal for publication within six months of receiving the Award. The manuscripts of non-winning entrants will be destroyed.
7. Within six months of the completion of the approved travel, the winner must make a technical report of 1500-2000 words to the Editor of the ANZSNM Journal for publication.
JUDGING
Papers submitted for the Award shall be judged by a panel of one Senior Researcher and one physician nominated by the Society and a representative of ANSTO. The judges must not be drawn from the same department as any candidate. The panel reserves the right not to make an award if it is deemed the standard is not sufficiently high. A simple majority vote of the panel (2) will govern all decisions. The panel shall meet prior to the first presentation to ensure that the judging criteria are understood.
The assessment for the Award will be on the basis of the following:
(a) Significance and merit of the data or procedure = 40%
(b) Scientific method of investigation or development = 30%
(c) Originality = 20%
(d) Presentation skills = 10%
THE AWARD
The Award will be for $3000 for documented expenses incurred to attend an international nuclear medicine meeting, eg. the Society of Nuclear Medicine or the European Association of Nuclear Medicine.
The successful applicant must provide ANSTO with his or her travel itinerary within six months of winning the Award.
ANZAPNM Registrar Award
GUIDELINES
The Award shall be known as The ANZAPNM Reigstrar Award. The Award is open to advanced trainees in nuclear medicine or to full-time research registrars in nuclear medicine, as part of a training program approved by the Joint Specialist Advisory Committee of the Royal Australasian College of Physicians (RACP) and the Royal Australian and New Zealand College of Radiologists (RANZCR). Recently qualified trainees may enter, provided that the work for the presentation was carried out during the period of training and is presented at the first Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) after completion of training. Entries are limited to one per candidate. Entrants must be financial members of the ANZSNM at the time of presentation.
The Award is for work that provides new and significant data of clinical and Scientific merit and involves the use of nuclear medicine techniques.
The data will be presented as an oral paper at the Annual Scientific Meeting of the ANZSNM. Notification should be given with the submission of the abstract that the presenter wishes to be considered for the Award.
The candidate must provide a statement, countersigned by his or her department head, indicating the extent of assistance received during the course of the work. This statement plus four copies of the paper must be received by the ANZAPNM Secretariat no later than two weeks prior to the ANZSNM Scientific Meeting.
The recipient of the Award shall provide a summary of the paper to both the ANZSNM and to the ANZAPNM Secretariat, for publication in the ANZSNM Journal and the ANZAPNM Newsletter and/or website. Successful candidates wishing to submit their work to a peer-reviewed medical journal may be permitted to do so after consulting with the ANZAPNM President.
Papers submitted for the Award shall be judged by a panel of two physicians and one scientist, nominated by the ANZAPNM. Each member of the juding panel shall declare any conflict of interest, and shall not judge any paper submitted by a candidate from his/her department. The Award will be made at the discretion of the judges.
The weightings for the Award will be as follows:
(a) Significance and merit of the data - 40%
(b) Scientific method of the investigation - 30%
(c) Oral presentation skills - 20%
(d) Originality - 10%
The Award will be for travel up to A$3,000 to enable attendance at an approved nuclear medicine meeting. All details and bookings for the trip shall be finalised by 31 March of the year following presentation of the Award.
The judging panel reserves the right not to make an Award in any year.
The Award is administered by the ANZAPNM. All correspondence relating to the Award should be made to the ANZAPNM Secretariat, P O Box 73, Balmain NSW 2041 Australia.
(Published ANZ Nuclear Medicine June 2003)
Mallinckrodt Award for Nuclear Medicine Technologist
INTRODUCTION
The Mallinckrodt Award will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM). Its aim is to foster the spirit of innovation and progress in nuclear medicine.
The Award will be provided for an oral scientific or technical paper presented by an Accredited nuclear medicine technologist.
DEFINITION FOR THE PURPOSE OF THIS AWARD
(a) Technologist: A financial member of the ANZSNM who is employed as an Accredited technologist in the field of nuclear medicine or who has enrolled in the PDY/Mentor Program and who has been a financial member of the Society for at least six months.
(b) Scientific or technical paper: A paper constructed in the following format. Objectives, Materials/Methods, Results, Discussion and Conclusions
ENTRIES FOR THE AWARD
This Award will be made on investigational or other work presented orally at the ASM by the entrant.
Entries will be considered on their value in improving knowledge in any aspect of nuclear medicine. While the study need not be totally original, considerable attention will be paid to the basic idea, to the individual effort and to the lack of dependence on non-technical aspects such as scan interpretation or clinical assessment. The fundamental requirements of any scientific paper, such as clarity of description of the studied problem in the context of published data, critical evaluation of results, utilisation of statistical or other relevant methodologies, as well as the presentation itself, will be taken into account. Acknowledgment of people or agencies that have contributed substantially to the work must the included.
A candidate for the Award must submit an abstract for the ASM as with any other paper. Submission of abstracts must be in accordance with the requirements of the ASM.
All papers submitted for the award will be considered on their merits as to eligibly and final acceptance.
An Accredited technologist entering for the Award shall provide a personally signed statement countersigned by the department head, indicating the extent of assistance given by others so that the judges can make an assessment of the proportion of the work done by the author(s) of the paper. This statement, plus an electronic copy and one hard copy of the full manuscript, shall be in the hands of the Professional Conference Organiser (PCO) at least three weeks prior to the beginning of the Conference.
The audience will be informed that the paper is an entry for the Award.
The recipient(s) of the Award must undertake to submit a copy of the manuscript to the Editor of the Society's Journal for publication within two months of winning the Award. All manuscripts of non-winning entrants submitted to the PCO will be destroyed.
MANUSCRIPT SUBMISSION FORMAT: Submitted on disc or by email in Microsoft Word. Any figures (graphics) should be submitted with the electronic copy as separate jpg files. Forward one complete hard copy. Each A4 page should be double spaced with font size of at least 10 points and paragraph indentation of at least 5 spaces.
Components of each manuscript must be submitted in the following order:
1. Title Page
2. Abstract
3.Text
4.Acknowledgments
5.References
6.Tables & Figure legends Pages should be number consecutively
FINANCIAL SUPPORT
If a candidate for the Award requires financial support to attend the ASM in order to present a paper, application should first be made to the employer. If this is unsuccessful, and the entrant wishes to seek support from the Society, application should be made to the local branch of the Society at least two months prior to the ASM.
Applications will be considered by each branch and a decision made on which author or authors it wishes to recommend that financial support be given. Such a decision will usually be based upon a presentation of the paper at a local branch meeting. The decision should then be forwarded to the Secretary not less than one month prior to the ASM.
The Executive of the Society will decide on the amount of money which the Society could provide and will advise the candidate through the Society. (The local branch is free to support a candidate with additional assistance.)
JUDGING
The judging panel shall consist of three Society members. One should be the President of the ANZSNM or their nominee, who shall act as Chairman. One of the two remaining judges shall be a nuclear medicine technologist for whom no conflict of interest can be identified. A judge must not belong to the same department as a candidate.
The criteria upon which judgment will rely shall include the following (percentages are maxima):
(a) The value of the paper as a contribution to nuclear medicine technology - 25%
(b) The extent of direct assistance the author(s) receive from supervisors or other individuals
(c) The content of the paper (accuracy, logic, statistical consideration, originality, etc) - 50%
(d) The technique of presentation (clarity, expression, quality and use of slides, timing, handling of questions, etc) - 25%
The judges will have discretion as to whether an Award will be made. The successful candidate will receive a suitably inscribed trophy.
AWARD
The award will consist of $1500 to be put towards a CPD activity of the winner's choice. In the case of multiple author entries, the Award will be shared.
A submission must be made to the Secretary of the ANZSNM outlining the proposed use of the Award prize money.
If the $1500 is used for attendance at an Australian or overseas conference, a technical report of 1500-2000 words should be submitted to the Editor for publication in the Society's Journal. This should be completed within six months of the travel.
Radpharm Award
RADPHARM Case Presentation Award Rules 2008
(Reviewed March 1999; Revised June 2008; Approved 10th July 2008)
1. The RADPHARM Technologist Case Presentation Award, hereafter termed the Award, will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), hereafter termed the Society.
2. Entries to the Award will be Nuclear Technologists employed within the field of Nuclear Medicine. Such entries will have been financial members of the Society for at least 6 months at the time of presentation at the ANZSNM ASM. Students undertaking an approved course of study in Nuclear Medicine are eligible to enter.
3. The Award will be made for an Oral Case Presentation of a single (One (1)) patient's study(s) performed within the Nuclear Medicine workplace.
4. The Award comprises two (2) parts. An initial Sponsorship (part 1) will be made to the winning entrant in the Home State. The
4.1 Previous State Winners may submit and present further case studies, however, they will be ineligible to become the State Winning Entrant for a period of two years.
5. Entrants to Part I and Part 2 of the Award must present their case study in the same year, the case unchanged in the intervening period.
6. PART l. Sponsorship
6.1 Entries for the Award are to present an oral case study in their Home State or in New Zealand (NZ) or at a pre-arranged Rural site. The Home State/NZ/Rural site shall be the region in which:
a) the entrant is employed/studying in the field of Nuclear Medicine and,
b) where the case study was obtained.
6.2 The Home States in Australia shall be deemed one of the following:
a) NSW
b) QLD
c) SA (including NT)
d) ACT
e) VIC (including Tasmania)
f) WA
6.3 The Rural entrant must fulfil one (1) of the following eligibility criteria:
a) employed in a department in an RRMA (Rural Remote Metropolitan Area) classified rural or remote area (see Appendix A)
b) a department more than 200km from their state capital
c) a department more than 100km from any other Nuclear Medicine Department
d) a department more than 200km from their relevant branch meeting.
6.4 Entrants to the Award are to present to the State/NZ Branch representative of the ANZSNM Technologist Group (ANZSNMT) a signed statement, countersigned by the department head indicating the extent of assistance received during the course of the case study work. In the case of a video presentation this statement should also confirm that the presentation was performed in accordance with the Rules and that the video has not been edited.
6.5 The winner of the State/NZ/Rural sponsoring will be required to provide this statement to the Hon. Secretary ANZSNMT on submission of the abstract to Part 2 of the Award.
6.6 Entrants to the Award {Part l and 2}, are to present their case study in a maximum of ten (10) minutes. The total presentation time will be divided as:
a) oral case presentation -7 minutes (maximum)
b) question time -3 minutes (maximum)
6.7 The State Branch/NZ Branch representative of the ANZSNMT will organise a venue and time for the presentation of case by entries to the Award, in the year prior to the ASM of the Society each year. Entrants to the Award who are normally located remotely from the presentation venue may submit a video presentation, performed before an audience of professional healthcare colleagues, to be viewed by the audience and judges at the presentation meeting. The current entrant will be available via telephone link to answer questions from the presentation meeting.
6.8 Judges for the State/NZ sponsorships shall determine the winning case presentation. The home State/NZ/Rural entrant awarded the sponsorship shall be termed a National or NZ finalist.
6.9 The State/NZ/Rural sponsorships shall be Judged by a panel of three (3) Nuclear Medicine Technologists. The panel will be nominated by the State Branch representative of the ANZSNMT. The panel must include the nominated State representative of the ANZSNMT. All panel members are to be full financial members of the Society, and eligible for accreditation. Where possible the judging panel should not be drawn from the same workplace/department as any entry to the award.
6.10 If there is only one case presentation within a State/NZ/Rural, the case study must be presented to a panel of three (3) Nuclear Medicine Technologists at a presentation night or Branch meeting. The panel of judges must judge whether the presentation is worthy and hence eligible for the Sponsorship. If judged to be unworthy, there will be no winner from that Home State or NZ.
6.11 The National and NZ finalist will be sponsored by RADPHARM/GMS for full registration to attend the Technologist Symposium of the ASM, to present their winning case study. Winners of Part 1 Sponsorship are the only entrant to Part 2 of the Award.
7. PART 2 The Award
7.1 National and NZ finalists must submit an abstract of their winning case presentation for the Technologist Symposium as with any paper. Submission of abstract must be in accordance with the requirements of the ASM.
7.2 The audience will be informed that the presentation is an entry for the RADPHARM Technologist Case Presentation Award
7.3 The Award will be judged by a panel of seven (7) Nuclear Medicine Technologist representatives, each nominated by their State/NZ Branch representative of the ANZSNMT. The judging panel must not be drawn from the same department/workplace as entry to the Award.
8. The Sponsorship and the Award will be decided on the following criteria with value specified,
a) - Originality
b) - Presentation
c) - Content (Correlative Investigations may be used.)
d) - Interest/Value of paper to Nuclear Medicine
e) - Contribution of Nuclear Medicine to patient management.
9. The RADPHARM Technologist Case Presentation Award will be presented at the conclusion of the Conference.
10. The recipient of the Award should provide to the ANZSNMT Honorary Secretary, an appropriate summary of the case study presentation for publication in the ANZSNM Journal.
APPENDIX A:
The Rural, Remote and Metropolitan Area (RRMA) classification was developed in 1994 by the Department of Primary Industries and Energy, and the then Department of Human Services and Health, which is now the Australian Institute of Health and Welfare. (1)
Seven (7) categories are included in this classification - 2 metropolitan, 3 rural and 2 remote. The classification is based on Statistical Local Areas (SLA) and allocates each SLA in Australia to a category based primarily on population numbers and an index of remoteness. The index is used to allocate non-metropolitan SLAs to either the rural or remote zone.
Zone/Category
Metropolitan zone
M1 Capital cities
M2 Other metropolitan centres (urban population > 100,000)
Rural zone
R1 Large rural centres (urban centre population 25,000 - 99,999)
R2 Small rural centres (urban centre population 10,000 - 24,999)
R3 Other rural areas (urban centre population < 10,000)
Remote zone
Rem1 Remote centres (urban centre population > 4,999)
Rem2 Other remote areas (urban centre population < 5,000)
The RADPHARM award eligibility criteria refers only to the Rural and remote classification zones.
Reference:
1. http://www.aihw.gov.au/ruralhealth/methodology/rrma.cfm